Home

Danaher Corp (DHR)

223.90
+0.82 (0.37%)

Danaher Corporation is a global science and technology company that designs, manufactures, and markets a diverse range of industrial and healthcare products and solutions

The company's operations are organized into several segments, including life sciences, diagnostics, dental, and environmental and applied solutions. Danaher focuses on advancing vital sciences and technologies through innovative products and services that enhance the quality of life. With a commitment to customer satisfaction, the company leverages its extensive expertise in engineering and manufacturing to deliver reliable and efficient solutions across various industries, helping to drive improved outcomes in healthcare, environmental monitoring, and industrial processes.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close223.08
Open223.30
Bid223.79
Ask224.01
Day's Range222.40 - 227.50
52 Week Range221.34 - 281.70
Volume2,494,635
Market Cap161.70B
PE Ratio (TTM)42.73
EPS (TTM)5.2
Dividend & Yield1.080 (0.48%)
1 Month Average Volume3,444,737

News & Press Releases

Danaher’s (NYSE:DHR) Q4 Sales Beat Estimates
Diversified science and technology company Danaher (NYSEDHR) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 2.1% year on year to $6.54 billion. Its non-GAAP profit of $2.14 per share was 1.3% below analysts’ consensus estimates.
Via StockStory · January 31, 2025
Here's How Much You Would Have Made Owning Danaher Stock In The Last 10 Yearsbenzinga.com
Via Benzinga · January 30, 2025
Broad-Based Sector Growth Expected For 2025talkmarkets.com
Total earnings for the 112 S&P 500 companies that have reported results are up +10.8% from the same period last year on +5.5% higher revenues, with 80.4% beating EPS estimates and 68.8% beating revenue estimates.
Via Talk Markets · January 29, 2025
Danaher Analysts Cut Their Forecasts After Downbeat Earningsbenzinga.com
Via Benzinga · January 30, 2025
In today's session, there are S&P500 stocks with remarkable trading volume.chartmill.com
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below.
Via Chartmill · January 29, 2025
Beyond The Numbers: 5 Analysts Discuss Danaher Stockbenzinga.com
Via Benzinga · January 29, 2025
Danaher Unusual Options Activitybenzinga.com
Via Benzinga · January 28, 2025
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Todaybenzinga.com
Via Benzinga · January 15, 2025
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Todaybenzinga.com
Via Benzinga · January 2, 2025
Wednesday's session: top gainers and losers in the S&P500 indexchartmill.com
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Wednesday.
Via Chartmill · January 29, 2025
What's going on in today's session: S&P500 gap up and gap down stockschartmill.com
Curious about the S&P500 stocks that are gapping on Wednesday? Explore the gap up and gap down stocks in the S&P500 index during today's session.
Via Chartmill · January 29, 2025
Wednesday's pre-market session: top gainers and losers in the S&P500 indexchartmill.com
Pre-market stock analysis of S&P500 stocks on 2025-01-29: top gainers and losers in today's session.
Via Chartmill · January 29, 2025
Manhattan Associates, LendingClub And Other Big Stocks Moving Lower In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · January 29, 2025
Here's How Much You Would Have Made Owning Danaher Stock In The Last 10 Yearsbenzinga.com
Via Benzinga · December 24, 2024
14 Analysts Have This To Say About Danaherbenzinga.com
Via Benzinga · December 23, 2024
Stocks Tick Down Ahead Of Fed Meeting, Nvidia Jitters Resume, Trump Media Rallies: What's Driving Markets Wednesday?benzinga.com
Caution dominates Wednesday's midday trading session in New York as investors anxiously await the Federal Open Market Committee decision at 2 p.m. ET.
Via Benzinga · January 29, 2025
Danaher Q4: EPS Miss Expectations Amid Diagnostics Segment Lagbenzinga.com
Danaher's Q4 earnings missed expectations due to a decline in its diagnostics segment, despite stronger sales in biotechnology and life sciences.
Via Benzinga · January 29, 2025
Jim Cramer Recommends Buying 'Fabulous' BlackRock, Calls Coterra Energy The 'Cheapest' Natural Gas Companybenzinga.com
Cramer comments on Danaher, Coterra, BlackRock and Digital Realty. As for Grail, "Just great science, but it is parabolic," he adds.
Via Benzinga · January 28, 2025
Earnings Scheduled For January 29, 2025benzinga.com
Via Benzinga · January 29, 2025
3 Insanely Cheap Stocks to Buyfool.com
The object is to buy low and sell high.
Via The Motley Fool · January 25, 2025
Goldman Sachs Predicts Gradual Recovery For Tools And Contract Research Sector In 2025, Stable Large Pharma Spending Key To Recoverybenzinga.com
Goldman Sachs predicts a gradual recovery for Life Sciences Tools in 2025, with bioprocessing gaining traction and improved investor sentiment likely.
Via Benzinga · January 24, 2025
Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications
Aldevron, a global leader in the production of DNA, RNA and protein, has launched its latest innovation, Alchemy™ cell-free DNA technology. This revolutionary technology represents a significant advancement in synthetic DNA manufacturing, offering a cell-free, enzymatic process to generate linear DNA (linDNA) templates for in vitro transcription (IVT) synthesis of mRNA molecules.
By Aldevron · Via Business Wire · January 21, 2025
5 High-Flying Stocks In Dan Loeb's Portfolio: Cinemark, Corpay, Amazon Leadbenzinga.com
Dan S. Loeb, founder of Third Point, a $7B hedge fund, is known for bold activist strategies that drive transformation in global companies.
Via Benzinga · December 20, 2024
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yetbenzinga.com
The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and the reasons why the stocks may be drawing attention.
Via Benzinga · December 13, 2024
Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analystbenzinga.com
BofA upgrades Danaher and Revvity, predicting a mixed but improving outlook for life sciences tools in fiscal year 2025 amid ongoing market challenges.
Via Benzinga · December 13, 2024